Stingray Bio develops precision therapeutics targeting the LMTK3 kinase to treat breast cancer. By utilizing structural biology and cancer pharmacology, the company aims to provide healthcare providers and drug developers with effective agents for novel cancer treatments.
Funding
$510K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers, including breast cancer, express the LMTK3 kinase, which promotes tumor growth and resistance to therapy. Current cancer treatments often lack specificity, leading to off-target effects and limited efficacy in patients with LMTK3-driven tumors. There is a need for more precise and effective therapies that selectively target LMTK3 to improve patient outcomes.
Solution
Stingray Bio is developing precision therapeutics that target the LMTK3 kinase to treat cancer. By leveraging structural biology and cancer pharmacology, Stingray Bio aims to create highly selective inhibitors of LMTK3. These inhibitors are designed to disrupt LMTK3's role in promoting tumor growth and resistance, potentially leading to more effective and targeted cancer treatments. The company's approach focuses on providing healthcare providers and drug developers with novel agents that can address the unmet needs of patients with LMTK3-driven cancers.
Target Audience
The primary target audience includes healthcare providers specializing in cancer treatment and drug developers seeking novel therapeutic agents for cancer.
Features
- Development of small molecule inhibitors specifically targeting the LMTK3 kinase.
- Utilization of structural biology to design highly selective inhibitors.
- Application of cancer pharmacology to optimize drug efficacy and minimize off-target effects.